Latest news

• Novartis eyes potential new indication for Cosentyx

  This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).

• J&J's Tremfya filed for approval in US for psoriatic arthritis

  This includes Novartis’ Consentyx (secukinumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate) , which are all already approved in psoriatic arthritis.

• NICE backs Pfizer’s Xeljanz for RA

  But UK’s cost-effectiveness watchdog removes two drugs from CDF. Pfizer is celebrating a positive recommendation from the National Institute for Health and Care Excellence (NICE) for Xeljanz (tofacitinib citrate), ... alone. Mason added: “We are

• Pfizer closes on Xeljanz filing in ulcerative colitis

  Xeljanz (tofacitinib) is already approved to treat rheumatoid arthritis (RA) but has failed to grow as quickly as hoped in that setting, so the US pharma giant is hoping new indications ... In addition to UC, the FDA approved Xeljanz XR (tofacitinib

• Pfizer to work with genetics firm on bowel disease

  Pfizer has existing interests and expertise in the area, including the autoimmune therapy Xeljanz (tofacitinib citrate), which is currently approved for rheumatoid arthritis in certain regions and is being investigated in